1 We next tested 149 known cancer risk loci for eQTL effects, a
2 We next tested for ethanol-induced changes in striatal-relate
3 We next tested signaling through chimeras between the Galpha(
4 We next tested the abilities of both Dr(+) E. coli and a Dr(-
5 We next tested the ability of transduced DCs to raise class I
6 We next tested the capacity for hair cell regeneration follow
7 We next tested the causal link between the correlative human
8 GF can be cleaved to tcHGF by plasminogen activators (PAs),
we next tested the cultures for active PA.
9 We next tested the current linear model for polarity establis
10 tion normalizes PPI deficits evoked from nucleus accumbens,
we next tested the degree to which VP inhibition would normal
11 We next tested the effects of primaquine and dynasore on SK2
12 We next tested the effects of SMIT1 co-expression, in the abs
13 We next tested the effects of the influenza virus inhibitors
14 We next tested the functional role of TGFbeta/activin/nodal s
15 We next tested the hypothesis that caspase activation led to
16 Based on this evidence,
we next tested the hypothesis that COX expression might promo
17 Because both features were also found in intron 13,
we next tested the hypothesis that intron 13 would be involve
18 On the basis of previous studies,
we next tested the hypothesis that NO decreases RhoA activity
19 e sensitivity of oxyR oprL bacteria to planktonic H(2)O(2),
we next tested the hypothesis that the biofilm mode of growth
20 We next tested the hypothesis that the SNAT4 isoform is funct
21 We next tested the in vitro and in vivo efficacy of vemurafen
22 We next tested the in vivo relevance of these findings using
23 We next tested the requirement for proliferation and migratio
24 learn the mechanism of thrombin-stimulated iPLA2 activity,
we next tested the role of p38 MAPK.
25 We next tested the selectivity of this system for BCC.
26 matrix protein, is highly expressed in both types of cells,
we next tested,
using a transgenic approach, whether a 9.6-kb
27 We next tested various mutant forms of the FAC polypeptide fo
28 We next tested whether CD40, whose engagement delivers a pote
29 We next tested whether CD40-induced signaling pathways were d
30 We next tested whether Follistatin suppresses Myostatin activ
31 d Ras-Raf-induced NF-kappa B activation in monocytic cells,
we next tested whether HIV-induced NF-kappa B activation was
32 We next tested whether P. carinii genomic cdc2 (with six intr
33 We next tested whether the alterations in perinucleolar heter
34 We next tested whether the DDD or DDE mutants cleave single-s
35 orine to tacrolimus is an effective treatment for early CR,
we next tested whether these two immunosuppressive drugs dire